Buy Jubilant Pharmova; target of Rs 850: ICICI Direct
ICICI Direct is bullish on Jubilant Pharmova has recommended buy rating on the stock with a target price of Rs 850 in its research report dated July 24, 2021.
July 28, 2021 / 09:43 AM IST
ICICI Direct's research report on Jubilant Pharmova
Jubilant Pharmova is engaged in specialty pharmaceuticals, CDMO, generics, drug discovery and proprietary novel drug businesses. Formulations - 24% of FY21 revenues, Radiopharma and allergy therapy – 38%, and CDMO & API – 33% of sales It has six USFDA approved manufacturing facilities in India, US and Canada
Despite regulatory concerns, we remain positive and retain our BUY rating on the stock We value Jubilant at Rs 850 i.e. 10x P/E on FY23E EPS
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.